BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With the recent clinical validation by BMS\, LAG-3 combination
 s are spearheading the next wave of immune checkpoint inhibitors. As such
 \, there has been an explosion of interest and high-scale investment into
  this exciting space.\n\nArriving at a critical point for LAG-3 developme
 nt\, the first ever LAG-3 Targeted Drug Development Summit is the definit
 ive industry-led event focused on propelling this next generation inhibit
 or to clinical use.\n\nEnsure your LAG-3 program reaches full clinical po
 tential through hearing from experts discuss:\n\nThe progress that has be
 en made and challenges faced in bispecific antibody based approaches\n\nI
 mproving combination therapy regimens\n\nBetter understanding the underpi
 nning biology of LAG-3 as a cancer target\n\nUtilizing biomarkers to unde
 rstand the interplay between PD-1 and LAG-3\n\nJoin translational and cli
 nical experts in LAG-3 development from Roche\, BMS\, F-STAR\, Regeneron\
 , Immutep\, Macrogenics\, University of Pittsburgh and more.\n
DTEND:20220127T163000
DTSTAMP:20260512T232942Z
DTSTART:20220125T090000
LOCATION:Online\, Virtual\, Digital\, New York\, New York\, 10000\,
SEQUENCE:0
SUMMARY:With the recent clinical validation by BMS\, LAG-3 combinations ar
 e spearheading the next wave of immune checkpoint inhibitors. As such\, t
 here has b...
UID:7de1b918-d959-4e1c-a452-8e5bb3d0e352
END:VEVENT
END:VCALENDAR